A carregar cotações...

Previsão

O preço-alvo médio dos analistas é € 2,12 (+606,67%). A mediana é € 1,82 (+506,67%).

Comprar
  6
Manter
  0
Vender
  0

Discussões na comunidade

Ainda não há nenhuma discussão sobre este ativo.

Iniciar discussão

  • Tenaya Therapeutics receives RMAT designation for gene therapy TN-401

    The FDA has granted RMAT designation to Tenaya Therapeutics' AAV9-based gene therapy TN-401 for PKP2-associated arrhythmogenic right ventricular cardiomyopathy. The decision is based on interim RIDGE-1 Phase 1b/2 data showing lower rates of premature ventricular contractions and non-sustained ventricular tachycardias. TN-401 already had Fast Track and orphan drug status; the RMAT designation enables expanded interactions with the FDA and may open accelerated approval pathways. Tenaya plans to present additional RIDGE-1 data and an update on regulatory plans for a pivotal trial in Q4 2026. » Mais em de.investing.com


  • Tenaya presents promising gene therapy data and cites liquidity through Q3 2027

    At an investor conference, Tenaya reported positive early efficacy and safety data for its three clinical programs: TN-201 showed sustained improvements in six evaluable patients up to two years after a single dose, TN-401 reduced premature ventricular contractions by a median of 64%, and TN-301 is being readied for Phase II. Management is working on dose selection, regulatory alignment and development plans and expects clarity by the end of 2024. Tenaya reports cash runway through the third quarter of 2027, stressing that this provides time for several clinical and regulatory milestones before additional financing would be needed. » Mais em de.investing.com


  • Tenaya Therapeutics expects regulatory clarity and funding needs in fourth quarter

    At the Canaccord Growth Conference, Tenaya reported positive early safety and efficacy signals for gene therapies TN-201 and TN-401 and the reactivation of the small‑molecule program TN-301. Regulatory decisions on the design of approval‑relevant studies for TN-201 and TN-401, as well as details on TN-301, are expected in the fourth quarter and will determine further capital allocation. The company noted cash of roughly $78 million, expected to last into the third quarter of 2027, but stressed that additional financing will be required for the planned registration and Phase II studies. » Mais em de.investing.com


  • Tenaya reports positive interim results for gene therapy TN-401 in ARVC

    Tenaya presented interim results from the phase 1b/2 RIDGE‑1 study: in six patients a single infusion of TN‑401 led to a mean reduction in premature ventricular contractions of about 60–67% and the treatment was reported to be well tolerated. Biopsies showed presence of TN‑401 DNA and stable to slightly improved PKP2 protein levels; common adverse events were transient increases in troponin or transaminases. The EMA has granted TN‑401 PRIME status. Financial analyses highlight stronger liquidity than debt but note negative free cash flow, while analyst price targets range between $2 and $8. » Mais em de.investing.com


  • Tenaya Therapeutics receives Nasdaq warning over minimum share price and boosts stock plan

    Tenaya Therapeutics received a warning from Nasdaq because the closing price was below $1.00 for 30 consecutive trading days; the company has until July 27, 2026 to raise the price to $1.00 or more for at least ten trading days. The board increased the shares reserved for the 2024 Inducement Equity Incentive Plan by 2,161,000 to a total of 3,361,000 shares. At the same time, Tenaya plans a $60 million capital raise (50 million units at $1.20) and announced that the FDA lifted the clinical hold on the MyPEAK-1 study of TN-201; interim results from the Phase 1b RIDGE-1 study were also released, after which analysts lowered their price targets but maintained buy ratings. » Mais em de.investing.com

Em 2022, Tenaya Therapeutics já distribuiu € 1,13 em dividendos. A última distribuição ocorreu em março de 2022.

Dados financeiros da empresa

No último trimestre, Tenaya Therapeutics registou receitas de € 1,5 mi e um ganho líquido de -€ 16,72 mi
(EUR) setembro de 2026
YoY
Receitas 1,5 mi -
Ganho bruto 1,5 mi -
Ganho líquido -16,72 mi 3,23%
EBITDA -16,26 mi 3,67%

Dados fundamentais

Métrica Valor
Capitalização bolsista
€ 72,41 mi
Número de ações
227,93 mi
Máximo/mínimo de 52 semanas
€ 1,33 - € 0,27
Dividendos Não
Beta
2,88
PER (PE Ratio)
-0,71
PEG (PEG Ratio)
-0,02
P/VC (PB Ratio)
1,45
P/V (PS Ratio)
26,25

Perfil da empresa

Tenaya Therapeutics, Inc., uma empresa de biotecnologia, descobre, desenvolve e disponibiliza terapêuticas para doenças cardíacas nos Estados Unidos. Desenvolve os seus produtos através de plataformas de regeneração celular, terapia génica e medicina de precisão. A empresa está a desenvolver o TN-201, uma terapia génica baseada em vírus adeno-associado (AAV) para tratar a miocardiopatia hipertrófica genética (gHCM) causada por mutações haploinsuficientes no gene da proteína C3 de ligação à miosina (MYBPC3); e o TN-301, um inibidor de molécula pequena da histona desacetilase 6 (HDAC6i) para utilização na insuficiência cardíaca com fração de ejeção preservada (HFpEF) e na miocardiopatia dilatada genética (gDCM). Desenvolve também o TN-401, uma terapia génica baseada em AAV que trata a miocardiopatia arritmogénica genética do ventrículo direito (gARVC) causada por mutações no gene da placofilina 2 (PKP2); uma terapia génica baseada em AAV concebida para libertar o gene DWORF (dwarf open reading frame) no coração para a DCM; e o programa Reprogramming, uma abordagem baseada em AAV para a regeneração cardíaca, destinada a substituir as células cardíacas perdidas em doentes com insuficiência cardíaca devido a enfarte do miocárdio prévio. A empresa foi constituída em 2016 e tem sede em South San Francisco, Califórnia.

Nome
Tenaya Therapeutics
CEO
Faraz Ali
Sede South San Francisco, ca
EUA
Site
Setor
Cuidados de saúde
Indústria
Produtos farmacêuticos
Entrada em bolsa
30/07/2021
Colaboradores 70

Análise aprofundada

Símbolos de ticker

Bolsa Símbolo
NASDAQ
TNYA
🍪

Parqet  utiliza cookies. Saber mais